Related Experiment Videos
Meningococcemia as a model for testing the hypothesis of antisepsis therapies
1University of Texas Southwestern Medical Center, Dallas 75235-9063, USA. bgiroi@childmed.dallas.tx.us
Objective:
To critically review the advantages and disadvantages of pediatric meningococcemia as a model for testing antisepsis therapies.
Data Sources:
Research and review articles on the pathogenesis and treatment of human meningococcemia, as well as editorial commentaries discussing the failure of clinical trials for adult sepsis or Systemic Inflammatory Response Syndrome. Data from these sources are presented in the context of the author's experience as principal investigator in a large, randomized trial on children with invasive meningococcal disease.
Study Selection And Data Extraction:
Studies were selected to include aspects of epidemiology, pathophysiology, outcome prediction, and therapeutic trials.
Data Synthesis:
Compared with an adult sepsis population, meningococcemia is a single disease, diagnosed clinically with high reliability. Patients are previously healthy, without underlying medical or surgical conditions. In contrast to sepsis trials, nearly all patients with meningococcal disease receive effective antibiotics. Finally, meningococcemia most closely resembles animal models of endotoxin infusion, in which most antisepsis therapies have been highly effective. However, the meningococcal model carries major disadvantages, among them that meningococcemia is rare and rapidly progressive and patients are widely dispersed geographically. In addition, a wide range of experimental therapies is routinely provided in an attempt to preserve life or limbs.
Conclusions:
Meningococcemia is an ideal model of a rapidly progressive bacterial infection associated with marked endotoxemia. Problems with the model can be overcome by extensive pretrial logistic planning, as well as close coordination and cooperation with national regulatory agencies.
Insights
Pediatric meningococcemia offers a valuable model for sepsis antisepsis therapy testing due to its rapid progression and endotoxemia. However, its rarity and geographic dispersion present challenges for clinical trials.
Area of Science:
- * Infectious Disease Epidemiology
- * Clinical Trial Design
- * Bacterial Pathogenesis
Background:
- * Pediatric meningococcemia serves as a critical model for evaluating antisepsis therapies.
- * Adult sepsis and Systemic Inflammatory Response Syndrome (SIRS) trials have faced significant challenges.
- * Understanding the nuances of meningococcemia is crucial for advancing sepsis treatment research.
Purpose of the Study:
- * To critically review the advantages and disadvantages of using pediatric meningococcemia as a model for testing antisepsis therapies.
- * To assess the suitability of meningococcemia for clinical trials compared to adult sepsis models.
- * To identify key considerations for designing effective clinical trials using this pediatric model.
Main Methods:
- * Comprehensive literature review of meningococcemia pathogenesis, treatment, and clinical trial outcomes.
- * Analysis of editorial commentaries on adult sepsis and SIRS trial failures.
- * Integration of data with the author's experience in a large pediatric meningococcal disease trial.
Main Results:
- * Meningococcemia presents as a single, reliably diagnosed clinical entity in previously healthy children.
- * Unlike adult sepsis, patients with meningococcal disease typically receive effective antibiotics.
- * The model closely mimics animal endotoxin infusion studies, where antisepsis therapies show promise, but suffers from rarity, rapid progression, and geographic dispersion of cases.
Conclusions:
- * Pediatric meningococcemia is an ideal model for studying rapidly progressive bacterial infections with significant endotoxemia.
- * Challenges related to the model's rarity and dispersion can be mitigated through meticulous pretrial planning and regulatory cooperation.
- * Successful utilization of this model requires robust logistical strategies and collaboration with regulatory bodies.